The FDA’s approval of Ozempic to battle chronic kidney disease “allows us to more broadly address conditions within cardiovascular-kidney-metabolic syndrome, which affects millions of ...

President Donald Trump is executing a shock and awe strategy, burying the public in a smoky cloud of flamboyant proposals. Some, like ending birthright citizenship, are quickly slapped down in ...

Donald Trump is executing a shock and awe strategy, burying the public in a smoky cloud of flamboyant proposals. Some, like ending birthright citizenship, ...

The conversation surrounding health care reform has intensified in recent years, revealing deep divides in how we view personal responsibility, government intervention and public health ...

Eli Lilly and Company (NYSE:LLY), a leading pharmaceutical giant with a market capitalization of $724 billion, has been ...

Weight loss drugs are popular—but often expensive. Luckily, there are a few ways to lower the costs, which we explore in this article.

The U.S. government said on Wednesday it will aim for "greater transparency" in Medicare drug price negotiations under ...

The FDA's move may change how doctors treat chronic kidney disease, which, according to Ozempic maker Novo Nordisk, affects around 37 million Americans and is one of the leading causes of death in the ...

Its weight-loss drug policy would fall to Trump's pick for health secretary, Robert F Kennedy Jr, and Mehmet Oz, Trump's choice to lead Medicare and Medicaid services. But this could mean a potential ...

Kennedy is nominated to lead the Department of Health and Human Services, a position that would give him enormous control ...

A Medscape survey found that a strong majority of physicians believe high-risk patients should have easier access to new weight loss drugs.

A woman who lost 64 pounds on a compounded form of the weight loss drug semaglutide, marketed as Wegovy and Ozempic, started ...